SequelSEC

Faeth Therapeutics, Inc. FTH

Pharmaceutical Preparations · CIK 0001829802 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$22.29M
Fiscal year ended 2025-12-31
Free cash flow
-$20.47M
Fiscal year ended 2025-12-31

Faeth Therapeutics, Inc. (FTH) reported net income of -$21.08M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Faeth Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Faeth Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$22.29M-$32.61M-$37.06M-$50.19M-$37.48M-$19.45M
Net income-$21.08M-$30.16M-$34.10M-$48.59M-$36.79M-$20.10M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 1.26Mshares 1.26Mshares 27.95Mshares 30.70Mshares 27.71MUnavailable
Pretax income-$21.08M-$30.16MUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0UnavailableUnavailableUnavailableUnavailable
Diluted EPS$-16.72$-24.01$-1.22$-1.58$-1.33Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$11.33M$13.04M$18.76M$19.80M$15.82M$7.53M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Faeth Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$8.67M$9.99M$13.01M$17.80M$7.16M$16.60M
Total assets$22.90M$45.36M$74.37M$118.38M$153.22M$21.43M
Current assets$21.51M$41.93M$67.25M$108.59M$148.54M$20.08M
Total liabilities$4.31M$6.98M$9.48M$14.97M$6.71M$5.54M
Current liabilities$4.25M$5.45M$5.64M$9.07M$4.89M$4.83M
Total equity incl. NCI$18.59M$38.39M$64.90M$103.41M$146.51M-$56.44M
Temporary (mezzanine) equity$0UnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable$567.00K
Accounts payable$689.00K$244.00K$573.00KUnavailableUnavailableUnavailable

Cash flow

Faeth Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$20.45M-$24.67M-$32.02M-$39.03M-$30.26M-$17.70M
Capital expenditures$16.00K$146.00K$180.00K$321.00K$2.03M$1.21M
Investing cash flow$19.77M$22.44M$38.41M$49.95M-$143.12M-$1.40M
Financing cash flow-$645.00K-$787.00K-$11.17M-$287.00K$163.94M$35.45M
Net change in cash-$1.33M-$3.02M-$4.78M$10.64M-$9.44M$16.34M
Stock-based compensation$1.27M$3.14M$4.45M$5.81M$5.66M$1.49M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$10.38MUnavailableUnavailableUnavailable
Depreciation & amortization$122.00K$551.00K$571.00K$614.00K$685.00K$209.00K

Derived

Faeth Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$20.47M-$24.82M-$32.20M-$39.35M-$32.28M-$18.91M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio5.06x7.70x11.92x11.98x30.38x4.16x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FTH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 72336000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.